SJEPD030948_D1.RNA-Seq
EPN · EPN Tumor
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- EPN Tumor
- cancer_type
- EPN
- subtype
- EPN Tumor
- age_years
- 17.05
- e1_e2
- E2
- umap1_2d
- -7.236958122
- umap2_2d
- 1.024967305
- umap1_3d
- 0.379959625
- umap2_3d
- 4.437410161
- umap3_3d
- 0.80088603
- dataset
- EPN-StJude
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.420
- OXIDATIVE_PHOSPHORYLATION+0.410
- DNA_REPAIR+0.370
- PROTEIN_SECRETION+0.340
- E2F_TARGETS+0.260
- SPERMATOGENESIS+0.170
- BILE_ACID_METABOLISM+0.160
- G2M_CHECKPOINT+0.090
- UNFOLDED_PROTEIN_RESPONSE+0.070
- PEROXISOME+0.040
Top 10 suppressed
- IL6_JAK_STAT3_SIGNALING-0.470
- APICAL_SURFACE-0.430
- TNFA_SIGNALING_VIA_NFKB-0.430
- HYPOXIA-0.410
- INTERFERON_ALPHA_RESPONSE-0.370
- INTERFERON_GAMMA_RESPONSE-0.370
- INFLAMMATORY_RESPONSE-0.360
- MYOGENESIS-0.350
- KRAS_SIGNALING_UP-0.330
- ESTROGEN_RESPONSE_EARLY-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_CHDGRYHJ | medulloblastoma | — | 0.930 |
| 2 | MNG87 | — | — | 0.929 |
| 3 | BS_H4B5Y6S0 | medulloblastoma | — | 0.913 |
| 4 | BS_HKZENFDA | medulloblastoma | — | 0.907 |
| 5 | 7cd1f8af-7c1d-4a56-a617-b8debf493122 | — | — | 0.906 |
| 6 | BS_KYF0Q0E7 | medulloblastoma | — | 0.901 |
| 7 | SRR1797245 | — | cohortSC | 0.893 |
| 8 | BS_Z7PKVY9J | medulloblastoma | — | 0.892 |
| 9 | BS_SDCNP7MW | Ependymoma NOS | — | 0.892 |
| 10 | SRR1797277 | — | cohortSC | 0.892 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.420 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.410 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.370 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.340 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.260 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.170 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.090 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.070 | Idelalisib | — uncovered |
| PEROXISOME | 0.040 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.020 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.010 | Inavolisib | — uncovered |